[go: up one dir, main page]

AU2001244596A1 - Indolylpyrrole derivatives and cell death inhibitors - Google Patents

Indolylpyrrole derivatives and cell death inhibitors

Info

Publication number
AU2001244596A1
AU2001244596A1 AU2001244596A AU4459601A AU2001244596A1 AU 2001244596 A1 AU2001244596 A1 AU 2001244596A1 AU 2001244596 A AU2001244596 A AU 2001244596A AU 4459601 A AU4459601 A AU 4459601A AU 2001244596 A1 AU2001244596 A1 AU 2001244596A1
Authority
AU
Australia
Prior art keywords
indolylpyrrole
derivatives
cell death
death inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001244596A
Inventor
Rei Asakai
Miho Katoh
Mikiko Sodeoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sagami Chemical Research Institute
Original Assignee
Sagami Chemical Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sagami Chemical Research Institute filed Critical Sagami Chemical Research Institute
Publication of AU2001244596A1 publication Critical patent/AU2001244596A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001244596A 2000-03-30 2001-03-28 Indolylpyrrole derivatives and cell death inhibitors Abandoned AU2001244596A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000094908 2000-03-30
JP2000-94908 2000-03-30
PCT/JP2001/002584 WO2001074807A1 (en) 2000-03-30 2001-03-28 Indolylpyrrole derivatives and cell death inhibitors

Publications (1)

Publication Number Publication Date
AU2001244596A1 true AU2001244596A1 (en) 2001-10-15

Family

ID=18609876

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001244596A Abandoned AU2001244596A1 (en) 2000-03-30 2001-03-28 Indolylpyrrole derivatives and cell death inhibitors

Country Status (4)

Country Link
US (1) US20030087949A1 (en)
EP (1) EP1275646A4 (en)
AU (1) AU2001244596A1 (en)
WO (1) WO2001074807A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004026803A (en) * 2002-03-29 2004-01-29 Nof Corp Nerve cell death preventive
AU2003268033A1 (en) * 2002-07-26 2004-02-16 The General Hospital Corporation Systems and methods for cell preservation
EP3081214A3 (en) * 2003-08-29 2016-11-16 The Brigham And Women's Hospital, Inc. Inhibitors of cellular necrosis
US7678823B2 (en) 2004-10-04 2010-03-16 Myriad Pharmaceticals, Inc. Compounds for alzheimer's disease
US9216966B2 (en) 2004-10-04 2015-12-22 John Manfredi Compounds for Alzheimer's disease
JP4171061B2 (en) 2005-02-09 2008-10-22 アーキュール，インコーポレーテッド Maleimide derivatives, pharmaceutical compositions and their use for the treatment of cancer
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
AU2007234399A1 (en) * 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
KR20100024494A (en) 2007-06-22 2010-03-05 아르퀼 인코포레이티드 Quinazolinone compounds and methods of use thereof
WO2009002806A1 (en) 2007-06-22 2008-12-31 Arqule, Inc. Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
ATE522531T1 (en) 2007-06-22 2011-09-15 Arqule Inc INDOLYLPYRROLIDINE FOR THE TREATMENT OF CANCER
EP2381775A4 (en) 2008-12-23 2012-08-15 Harvard College SMALL MOLECULAR NEKTROPTOSIS HEMMER
WO2014136807A1 (en) * 2013-03-05 2014-09-12 国立大学法人 岡山大学 Cell-death inhibitor, and novel compound
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
JP2017538712A (en) 2014-12-11 2017-12-28 プレジデント アンド フェローズ オブ ハーバード カレッジ Cell necrosis inhibitor and method related thereto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028315A1 (en) * 1997-11-28 1999-06-10 Lg Chemical Ltd. Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
AU2548699A (en) * 1998-02-23 1999-09-06 Rei Asakai Cell death inhibitors
US6589977B1 (en) * 1999-02-09 2003-07-08 Sagami Chemical Research Center Pyrrole derivatives and cell death inhibitors

Also Published As

Publication number Publication date
WO2001074807A1 (en) 2001-10-11
EP1275646A1 (en) 2003-01-15
US20030087949A1 (en) 2003-05-08
EP1275646A4 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
AU2001258771A1 (en) -secretase inhibitors
AU2001240542A1 (en) Heterocyclic compounds and their use as parp inhibitors
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU7392101A (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU2548699A (en) Cell death inhibitors
AU2002230836A1 (en) Benzylamine derivatives and their use as thrombin inhibitors
AU2001285750A1 (en) Urokinase inhibitors
AU2001244596A1 (en) Indolylpyrrole derivatives and cell death inhibitors
AU2001267836A1 (en) Preservation fluid for cells and tissues
AU2002216650A1 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
AU2327700A (en) Pyrrole derivatives and cell death inhibitors
AU5213300A (en) 2-nh-pyridones and pyrimidones as mrs inhibitors
AU2001276027A1 (en) Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors
AU2002216223A1 (en) Preservation of cells
AU4501199A (en) 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
AU2001232809A1 (en) Gyrase inhibitors and uses thereof
AU2002258740A1 (en) Methods and compounds for decreasing cell toxicity or death
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU3235100A (en) Prothease inhibitors
AU2001277561A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
AU2001249409A1 (en) Ricin inhibitors and methods for use thereof
AU2001266124A1 (en) 2-aminothiazoline derivatives and their use as no-synthase inhibitors
AU2001295966A1 (en) Cell damage inhibitor